Related Experiment Videos
Hypoxia correlates with angiogenesis in cervical cancers
Hayahito Tanaka1, Yoshiko Yasuda, Terunaga Musha
1Department of Obstetrics and Gynecology, Kyorin University School of Medicine, Mitaka, Japan.
International Journal of Clinical Oncology
|February 25, 2005
Summary
Hypoxia in uterine cervix cancer correlates with increased vascularity. Vascular endothelial growth factor (VEGF) in cancer cells promotes blood vessel growth, suggesting a target for treatment.
Area of Science:
- Oncology
- Vascular Biology
- Cancer Research
Background:
- Tissue hypoxia induces angiogenic factors like vascular endothelial growth factor (VEGF) and erythropoietin.
- Previous studies showed erythropoietin promotes angiogenesis in gynecological malignancies.
- This study investigates hypoxia and its correlation with vascular density via VEGF in uterine cervix cancer.
Purpose of the Study:
- To determine if malignant uterine cervix tissue exhibits hypoxia.
- To assess the correlation between hypoxia and increased vascular density.
- To investigate the role of vascular endothelial growth factor (VEGF) in this process.
Main Methods:
- ATP content was measured in cervical cancer and normal tissues using liquid chromatography to assess hypoxia.
- Immunohistochemical microscopy was used to identify endothelial cells and VEGF distribution.
- Microvessel density was quantified in tissue sections.
Main Results:
- Cervical squamous cell carcinoma showed significantly lower ATP levels (indicating hypoxia) and higher vascular density compared to normal tissue.
- A significant inverse correlation was found between microvessel number and ATP content in cancer tissues.
- Vascular endothelial growth factor (VEGF) immunoreactivity was detected in the hyperplastic epithelium of squamous cell carcinoma.
Conclusions:
- Hypoxia is present in squamous cell carcinoma of the uterine cervix and correlates with increased vascularity.
- VEGF expressed in the hyperplastic epithelium likely promotes angiogenesis in this cancer.
- These findings suggest VEGF as a potential therapeutic target for uterine cervix cancer.